Welcome to our dedicated page for Cardiff Oncology news (Ticker: CRDF), a resource for investors and traders seeking the latest updates and insights on Cardiff Oncology stock.
Cardiff Oncology, Inc. (Nasdaq: CRDF) is a clinical-stage biotechnology company developing cancer therapies based on PLK1 inhibition, with its lead asset onvansertib in multiple clinical programs. The CRDF news page on Stock Titan aggregates company announcements, clinical data updates, financial results and investor event participation so readers can follow how the onvansertib development story evolves over time.
News coverage for Cardiff Oncology frequently highlights clinical trial milestones, such as enrollment completion and data readouts from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated metastatic colorectal cancer. Press releases also describe results from investigator-initiated studies, including onvansertib in combination with paclitaxel in metastatic triple negative breast cancer and monotherapy use in chronic myelomonocytic leukemia, as well as data presented at major scientific meetings like ASCO and ASH.
Investors and observers can also find quarterly financial results and business updates, where Cardiff Oncology reports on research and development spending, cash runway and key operational highlights, alongside commentary on the progress of onvansertib across different tumor types. In addition, the company regularly announces participation in healthcare and investor conferences, including fireside chats, corporate presentations and one-on-one meetings hosted by firms such as Piper Sandler, Guggenheim, Stifel, Wells Fargo, Morgan Stanley and others.
This news feed offers a centralized view of Cardiff Oncology’s disclosures, from clinical efficacy and safety data to patent developments and leadership changes. Readers interested in oncology drug development, PLK1 inhibition, or the CRDF ticker can use this page to track Cardiff Oncology’s ongoing activities and key communications to the market.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will participate in the William Blair Biotech Focus Conference 2022 on July 12-13, 2022, held at The St. Regis New York. The company aims to leverage its expertise in PLK1 inhibition to develop novel cancer therapies, particularly focusing on its lead asset, onvansertib, which targets treatment-resistant cancers. A pre-recorded fireside chat will be available on-demand starting July 11, 2022. For more details, visit Cardiff Oncology's website.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a biotechnology firm specializing in PLK1 inhibition for cancer therapies, will engage in a fireside chat and one-on-one meetings at the H.C. Wainwright Global Investment Conference in Miami, Florida, from May 23-26, 2022. The fireside chat is scheduled for May 24, 2022, at 5:00 PM ET. The event is a platform for the company to discuss its innovative therapies, particularly its lead asset, onvansertib, aimed at overcoming treatment resistance in various cancers. A replay will be available on their website following the event.
Cardiff Oncology (Nasdaq: CRDF) reported promising Phase 1b/2 results for its lead KRAS-mutated metastatic colorectal cancer program, showcasing an objective response rate (ORR) of 34% compared to historical controls of 5-13%. Additionally, Phase 2 data from its metastatic castration-resistant prostate cancer trial indicated that 75% of patients on the highest dose achieved disease control. The company holds approximately $129.4 million in cash as of March 31, 2022, with increased operating expenses attributed to development efforts for onvansertib. These results position Cardiff for future growth and advancement in oncology.
Cardiff Oncology (Nasdaq: CRDF) announced the departure of its Chief Medical Officer, Katherine L. Ruffner, M.D., effective April 22, 2022. Dr. Ruffner will assist during the transition, while Sandra L. Silberman, M.D., Ph.D., will serve as the interim senior medical advisor overseeing clinical trials. The company's clinical development efforts for its primary drug candidate, onvansertib, remain on track. CEO Mark Erlander expressed gratitude for Dr. Ruffner's contributions and optimism for the year ahead.
Cardiff Oncology announced updated clinical data from its Phase 2 trial evaluating onvansertib combined with abiraterone and prednisone for metastatic castration-resistant prostate cancer (mCRPC). The trial shows increased disease control rates with higher dose densities of onvansertib—from 29% to 45% for PSA stabilization and 53% to 75% for radiographic stable disease. Median progression-free survival increased from 4.1 months to 13.2 months in patients receiving onvansertib. Genomic analysis suggests sensitivity to the combination treatment correlates with mutations in MTOR and PTEN.
Cardiff Oncology (Nasdaq: CRDF) announced promising results from preclinical studies at the AACR Annual Meeting, showcasing that the combination of onvansertib and the PARP inhibitor olaparib significantly improves survival in PARPi-resistant ovarian cancer models. The studies demonstrated that this combination therapy was well tolerated and effective against various PDX models, including both BRCA1-mutant and wild-type variants. These findings support further investigation into this treatment approach for overcoming resistance to PARP inhibitors in clinical settings.
Cardiff Oncology, a clinical-stage biotechnology company, announced that CEO Mark Erlander will present at the 2022 Virtual Growth Conference from March 28-30, 2022. The fireside chat is scheduled for March 28 at 2:30 PM ET. The conference will be hosted by Maxim Group LLC and streamed live on M-Vest. Additionally, Dr. Erlander will provide a pre-recorded overview of the company's clinical and corporate strategy. Cardiff Oncology focuses on developing therapies targeting cancers using its lead asset, onvansertib, a PLK1 inhibitor. For more information, visit their website.
Cardiff Oncology (Nasdaq: CRDF) announced the acceptance of two abstracts for poster presentations at the AACR Annual Meeting from April 8-13, 2022 in New Orleans. The presentations focus on their lead asset, onvansertib, a promising PLK1 inhibitor. The first abstract discusses biomarkers for mCRPC patients receiving onvansertib with abiraterone, while the second highlights combination therapy's potential against PARP inhibitor resistance. These findings aim to advance treatment options for cancer patients.
Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology firm, will join Cowen's 42nd Annual Healthcare Conference for a panel discussion and investor meetings from March 7-9, 2022. The panel, focusing on Gastrointestinal/Genitourinary Oncology, is scheduled for March 8, 2022, at 10:30 AM ET. Cardiff is advancing its lead drug, onvansertib, a third-generation PLK1 inhibitor, aimed at treating various cancers including KRAS-mutated colorectal cancer. A replay of the panel will be accessible on Cardiff's website for 30 days post-conference.
Cardiff Oncology (Nasdaq: CRDF) reported significant progress in its KRAS-mutated metastatic colorectal cancer (mCRC) program, with patient numbers increasing from 14 to 48. Initial data showed a robust objective response rate of 35% and a median progression-free survival (mPFS) of 9.4 months. A $15 million equity investment from Pfizer at a premium of 19% per share further supports the company's growth. Total operating expenses for Q4 2021 increased to $9.6 million, largely due to ongoing clinical programs. The company ended 2021 with approximately $141 million in cash.